Pages that link to "Q34201904"
Jump to navigation
Jump to search
The following pages link to Cyclophosphamide in lupus nephritis: a controlled trial (Q34201904):
Displaying 50 items.
- Cyclophosphamide versus methylprednisolone for treating neuropsychiatric involvement in systemic lupus erythematosus (Q24200954) (← links)
- Treatment for lupus nephritis (Q24202572) (← links)
- Cyclophosphamide versus methylprednisolone for treating neuropsychiatric involvement in systemic lupus erythematosus (Q24246092) (← links)
- Treatment for lupus nephritis (Q24247408) (← links)
- Late hemorrhagic cystitis following low-dose cyclophosphamide therapy (Q28328664) (← links)
- Treatment of patients with systemic lupus erythematosus including nephritis with chlorambucil (Q28363829) (← links)
- Pediatric lupus nephritis: Management update (Q28660110) (← links)
- The epidemiology of systemic lupus erythematosus: 1950-1990 conceptual advances and the ARAMIS data banks (Q30661190) (← links)
- Intensive immunosuppression versus prednisolone in the treatment of connective tissue diseases (Q33553829) (← links)
- Recent advances in the immunopathogenesis of systemic lupus erythematosus (Q33824546) (← links)
- Cyclophosphamide versus methylprednisolone for the treatment of neuropsychiatric involvement in systemic lupus erythematosus (Q33978636) (← links)
- Recent observations on central nervous system lupus erythematosus (Q33987313) (← links)
- Successful treatment of autoimmune disease in (NZB/NZW)F1 female mice by using fractionated total lymphoid irradiation (Q34038685) (← links)
- Problems with immunosuppressive agents in renal disease (Q34302895) (← links)
- Combination treatment in autoimmune diseases: systemic lupus erythematosus. (Q34309764) (← links)
- Randomized controlled trials in systemic lupus erythematosus: what has been done and what do we need to do? (Q35824537) (← links)
- Challenges in bringing the bench to bedside in drug development for SLE. (Q35968394) (← links)
- Emergence of targeted immune therapies for systemic lupus (Q36066014) (← links)
- Immunosuppressive Therapy in Rheumatic Disease (Q36269226) (← links)
- Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis (Q36302245) (← links)
- CD4+Foxp3+ regulatory T cells prolong drug-induced disease remission in (NZBxNZW) F1 lupus mice (Q36903043) (← links)
- Success using tacrolimus in patients with proliferative and membranous lupus nephritis and refractory proteinuria. (Q37150681) (← links)
- Theoretical and experimental approaches to generalized autoimmunity (Q37783216) (← links)
- Mechanisms of action and clinical applications of cytotoxic drugs in rheumatic disorders (Q38591478) (← links)
- Cytotoxic agents in childhood glomerulonephritis (Q39508879) (← links)
- Comparison of chlorambucil, azathioprine or cyclophosphamide combined with corticosteroids in the treatment of lupus nephritis (Q39536979) (← links)
- The treatment of lupus nephritis (Q39749422) (← links)
- Cyclophosphamide protection in nzb/nzw disease. Mechanisms and therapeutic regimens (Q39761788) (← links)
- Corticosteroid Therapy of the Collagen Vascular Disorders (Q39937928) (← links)
- Clinical pharmacology and toxicology of cyclophosphamide: emphasis on use in rheumatic diseases (Q40154586) (← links)
- Cyclophosphamide (Cytoxan). A review on relevant pharmacology and clinical uses (Q40197212) (← links)
- Reactivities of systemic lupus erythematosus sera with cellular and virus antigen preparations (Q40202542) (← links)
- Genetic and immune aspects of systemic lupus erythematosus (Q40218886) (← links)
- The effect of immunosuppressive chemotherapy on immune function in patients with malignant disease (Q40479239) (← links)
- Clinical use of immunosuppressive drugs: part I (Q40497391) (← links)
- The mechanism of action of cyclophosphamide on the nephritis of (NZB x NZW)F1 hybrid mice (Q40653535) (← links)
- Cyclophosphamide treatment in polyarteritis nodosa (Q40807892) (← links)
- Treatment of lupus nephritis: a meta-analysis of clinical trials (Q40906582) (← links)
- Cyclophosphamide therapy in systemic lupus erythematosus and polymyositis (Q40912817) (← links)
- Treatment of active chronic hepatitis with cyclophosphamide (Q41238343) (← links)
- The effect of microsomal enzyme inhibition on the immunosuppressive and toxic effects of cyclophosphamide (Q43515728) (← links)
- Oral cyclophosphamide without corticosteroids to treat mucous membrane pemphigoid (Q43789787) (← links)
- Efficacy of immunosuppressive drugs in rheumatic diseases (Q43840658) (← links)
- Glomerulonephritis — 1974 (Q44009488) (← links)
- Factors associated with chronic renal failure in 121 patients with diffuse proliferative lupus nephritis: a case-control study (Q44112212) (← links)
- Disease activity in the nephritis of systemic lupus erythematosus in relation to serum complement concentrations. DNA-binding capacity and precipitating anti-DNA antibody (Q44360884) (← links)
- A double-blind controlled trial comparing cyclophosphamide, azathioprine and placebo in the treatment of lupus glomerulonephritis (Q44482867) (← links)
- Comparison of therapeutic and immunosuppressive effects of azathioprine, prednisolone and combined therapy in NZP-NZW mice (Q44505272) (← links)
- Cytochrome P450 pharmacogenetics as a predictor of toxicity and clinical response to pulse cyclophosphamide in lupus nephritis (Q44973876) (← links)
- Favorable outcome in diffuse proliferative glomerulonephritis of systemic lupus erythematosus (Q45245883) (← links)